RhNAGLU: Phase I/II data

Top-line data from an open-label, U.S. and U.K. Phase I/II trial in 11 patients ages 2-10 with MPS IIIB showed that 1 and 3 mg/kg IV SBC-103 every other week reduced mean CSF heparan sulfate levels fr...